Recursion Pharmaceuticals: CMO Ramona Doyle departs; Shafique Virani appointed interim CMO

RECURSION PHARMACEUTICALS, INC.

Ramona Doyle's employment as CMO ended June 7, 2022.
Shafique Virani appointed interim CMO, effective June 7, 2022.
Virani continues to serve as chief business officer.
Virani previously served as interim CMO from March to December 2020.
Virani joined Recursion in March 2020; prior roles included CEO of BridgeBio subsidiaries.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ramona Doyle

Chief Medical Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2022-06-07
Successor: Shafique Virani
Filed: June 9, 2022, 7:59 PM ET

The employment of Ramona Doyle, MD as chief medical officer (“CMO”) of Recursion Pharmaceuticals, Inc. (the “Company”) ended on June 7, 2022.

Appointed (interim)

Shafique Virani

interim Chief Medical Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2022-06-07
Filed: June 9, 2022, 7:59 PM ET

Also, on June 7, 2022, the Company appointed Shafique Virani, MD FRCS, as interim CMO.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ramona Doyle departed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..

Action: ended
Role: Chief Medical Officer

Exact text from the filing

The employment of Ramona Doyle, MD as chief medical officer (“CMO”) of Recursion Pharmaceuticals, Inc. (the “Company”) ended on June 7, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Shafique Virani was appointed as interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: interim Chief Medical Officer

Exact text from the filing

Also, on June 7, 2022, the Company appointed Shafique Virani, MD FRCS, as interim CMO.

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-171124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.